FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901438513> ?p ?o ?g. }

• W2901438513 abstract "Mass drug administration (MDA) has the potential to interrupt malaria transmission and has been suggested as a tool for malaria elimination in low-endemic settings. This study aimed to determine the effectiveness and safety of two rounds of MDA in Zanzibar, a pre-elimination setting. A cluster randomised controlled trial was conducted in 16 areas considered as malaria hotspots, with an annual parasite index of > 0.8%. The areas were randomised to eight intervention and eight control clusters. The intervention included two rounds of MDA with dihydroartemisinin-piperaquine and single low-dose primaquine 4 weeks apart in May–June 2016. Primary and secondary outcomes were cumulative confirmed malaria case incidences 6 months post-MDA and parasite prevalences determined by PCR 3 months post-MDA. Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA. Intervention coverage was 91.0% (9959/10944) and 87.7% (9355/10666) in the first and second rounds, respectively; self-reported adherence was 82.0% (881/1136) and 93.7% (985/1196). Adverse events were reported in 11.6% (147/1268) and 3.2% (37/1143) of post-MDA survey respondents after both rounds respectively. No serious adverse event was reported. No difference in cumulative malaria case incidence was observed between the control and intervention arms 6 months post-MDA (4.2 and 3.9 per 1000 population; p = 0.94). Neither was there a difference in PCR-determined parasite prevalences 3 months post-MDA (1.4% and 1.7%; OR = 1.0, p = 0.94), although having received at least the first MDA was associated with reduced odds of malaria infection (aOR = 0.35; p = 0.02). Among confirmed malaria cases at health facilities, 26.0% and 26.3% reported recent travel outside Zanzibar in the intervention and control shehias (aOR ≥ 85; p ≤ 0.001). MDA was implemented with high coverage, adherence, and tolerability. Despite this, no significant impact on transmission was observed. The findings suggest that two rounds of MDA in a single year may not be sufficient for a sustained impact on transmission in a pre-elimination setting, especially when the MDA impact is restricted by imported malaria. Importantly, this study adds to the limited evidence for the use of MDA in low transmission settings in sub-Saharan Africa. ClinicalTrials.gov, NCT02721186 (registration date: March 29, 2016)" @default.
• W2901438513 created "2018-11-29" @default.
• W2901438513 creator A5010085183 @default.
• W2901438513 creator A5015312566 @default.
• W2901438513 creator A5022536367 @default.
• W2901438513 creator A5023341283 @default.
• W2901438513 creator A5025037358 @default.
• W2901438513 creator A5026755743 @default.
• W2901438513 creator A5028497037 @default.
• W2901438513 creator A5031248608 @default.
• W2901438513 creator A5034696429 @default.
• W2901438513 creator A5043581872 @default.
• W2901438513 creator A5053546594 @default.
• W2901438513 creator A5059299385 @default.
• W2901438513 creator A5063465178 @default.
• W2901438513 creator A5063755421 @default.
• W2901438513 creator A5068552989 @default.
• W2901438513 creator A5081075352 @default.
• W2901438513 creator A5084119337 @default.
• W2901438513 creator A5090110810 @default.
• W2901438513 date "2018-12-01" @default.
• W2901438513 modified "2023-10-09" @default.
• W2901438513 title "A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission" @default.
• W2901438513 cites W1549510969 @default.
• W2901438513 cites W1787098375 @default.
• W2901438513 cites W1966459680 @default.
• W2901438513 cites W1979668339 @default.
• W2901438513 cites W1982631140 @default.
• W2901438513 cites W2003156271 @default.
• W2901438513 cites W2055971230 @default.
• W2901438513 cites W2062863104 @default.
• W2901438513 cites W2069254344 @default.
• W2901438513 cites W2099115319 @default.
• W2901438513 cites W2099706549 @default.
• W2901438513 cites W2114625697 @default.
• W2901438513 cites W2124177928 @default.
• W2901438513 cites W2125987157 @default.
• W2901438513 cites W2127848106 @default.
• W2901438513 cites W2132895374 @default.
• W2901438513 cites W2144009871 @default.
• W2901438513 cites W2149473605 @default.
• W2901438513 cites W2158606409 @default.
• W2901438513 cites W2164752189 @default.
• W2901438513 cites W2302939988 @default.
• W2901438513 cites W2486735652 @default.
• W2901438513 cites W2555838895 @default.
• W2901438513 cites W2559952192 @default.
• W2901438513 cites W2560080836 @default.
• W2901438513 cites W2615045196 @default.
• W2901438513 cites W2617508148 @default.
• W2901438513 cites W2748937516 @default.
• W2901438513 cites W2751699411 @default.
• W2901438513 cites W2758125008 @default.
• W2901438513 cites W2783246805 @default.
• W2901438513 cites W2783983357 @default.
• W2901438513 cites W2793711844 @default.
• W2901438513 cites W2802085197 @default.
• W2901438513 cites W2889248076 @default.
• W2901438513 cites W2911448144 @default.
• W2901438513 doi "https://doi.org/10.1186/s12916-018-1202-8" @default.
• W2901438513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6287359" @default.
• W2901438513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30526588" @default.
• W2901438513 hasPublicationYear "2018" @default.
• W2901438513 type Work @default.
• W2901438513 sameAs 2901438513 @default.
• W2901438513 citedByCount "29" @default.
• W2901438513 countsByYear W29014385132018 @default.
• W2901438513 countsByYear W29014385132019 @default.
• W2901438513 countsByYear W29014385132020 @default.
• W2901438513 countsByYear W29014385132021 @default.
• W2901438513 countsByYear W29014385132022 @default.
• W2901438513 countsByYear W29014385132023 @default.
• W2901438513 crossrefType "journal-article" @default.
• W2901438513 hasAuthorship W2901438513A5010085183 @default.
• W2901438513 hasAuthorship W2901438513A5015312566 @default.
• W2901438513 hasAuthorship W2901438513A5022536367 @default.
• W2901438513 hasAuthorship W2901438513A5023341283 @default.
• W2901438513 hasAuthorship W2901438513A5025037358 @default.
• W2901438513 hasAuthorship W2901438513A5026755743 @default.
• W2901438513 hasAuthorship W2901438513A5028497037 @default.
• W2901438513 hasAuthorship W2901438513A5031248608 @default.
• W2901438513 hasAuthorship W2901438513A5034696429 @default.
• W2901438513 hasAuthorship W2901438513A5043581872 @default.
• W2901438513 hasAuthorship W2901438513A5053546594 @default.
• W2901438513 hasAuthorship W2901438513A5059299385 @default.
• W2901438513 hasAuthorship W2901438513A5063465178 @default.
• W2901438513 hasAuthorship W2901438513A5063755421 @default.
• W2901438513 hasAuthorship W2901438513A5068552989 @default.
• W2901438513 hasAuthorship W2901438513A5081075352 @default.
• W2901438513 hasAuthorship W2901438513A5084119337 @default.
• W2901438513 hasAuthorship W2901438513A5090110810 @default.
• W2901438513 hasBestOaLocation W29014385131 @default.
• W2901438513 hasConcept C120665830 @default.
• W2901438513 hasConcept C121332964 @default.
• W2901438513 hasConcept C126322002 @default.
• W2901438513 hasConcept C197934379 @default.
• W2901438513 hasConcept C203014093 @default.
• W2901438513 hasConcept C2776793103 @default.
• W2901438513 hasConcept C2777425658 @default.
• W2901438513 hasConcept C2778048844 @default.

• next